Finasteride Tablets

This product belongs to the 4-nitrogen steroid hormone compound, which is a specific type II 5α-reductase competitive inhibitor. It inhibits the conversion of peripheral testosterone into dihydrotestosterone and reduces the level of dihydrotestosterone in the blood, prostate, skin and other tissues. The growth, development and benign hyperplasia of the prostate depend on dihydrotestosterone. Finasteride inhibits prostate hyperplasia and improves the related clinical symptoms of benign prostatic hyperplasia by reducing the level of dihydrotestosterone in the blood and prostate tissue.

The main ingredient of this product is finasteride. Molecular weight: C23H36N2O2

This product is a special-shaped film-coated tablet, which appears white or off-white after removing the coating.

Finasteride tablets are 5-alpha reductase inhibitors and are the most commonly used drugs for the treatment of benign prostatic hyperplasia (BPH). They reduce the size of the prostate, relieve symptoms, increase urine flow rate, and delay disease progression through hormone regulation mechanisms.

Oral. Recommended dose: 5 mg (1 tablet) once a day, either on an empty stomach or with food.

Finasteride has good tolerance, and most adverse reactions are mild and short-lived. Literature reports: 1. Adverse reactions with an incidence rate of ≥1% are mainly sexual dysfunction (impotence, loss of libido, ejaculation disorder), breast discomfort (breast enlargement, breast pain) and rash. The incidence of adverse events after one year of use of this product is as follows (the brackets are the placebo control group), and the cumulative incidence of using this product for two to four years shows a downward trend. Impotence: 8.1% (3.7%). Loss of libido: 6.4% (3.4%). Decreased semen volume: 3.7% (0.8%). Ejaculation disorder: 0.8% (0.1%). Enlarged breasts: 0.5% (0.1%). Breast pain: 0.4% (0.1%). Rash: 0.5%. 2. Other adverse reactions reported after the product was launched include: allergic reactions such as itching, urticaria and swelling of the face and lips, and testicular pain. 3. Laboratory test results: When evaluating laboratory test results, the reduction in prostate-specific antigen (PSA) levels in patients taking finasteride should be taken into account. There were no differences in other standard laboratory parameters between patients taking finasteride or placebo.

This product is not suitable for women and children. This product is contraindicated in the following situations: 1. People who are allergic to any of the ingredients in this product. 2. Pregnant women or women who may become pregnant.

Precautions for children: This product is not suitable for children. Precautions for pregnancy and lactation: This product is contraindicated for women who are pregnant or may become pregnant. Precautions for the elderly: No clinical studies have been conducted on the use of this product in the treatment of male pattern baldness in elderly male patients.

No clinically significant drug interactions have been identified. 1. Finasteride has no significant effect on the cytochrome P450-related drug metabolizing enzyme system. Compounds that have been tested in men include propranolol, digoxin, glibenclamide, warfarin, theophylline, and antipyrine, none of which have been found to have clinically significant interactions with finasteride. 2. Other combination therapies. Although no specific drug interaction studies have been conducted, in clinical studies, finasteride has been shown to interact with angiotensin-converting enzyme inhibitors, acetaminophen, acetylsalicylic acid, alpha-blockers, beta-blockers, calcium channel blockers, nitrates for heart disease, diuretics, H2 antagonists, HMG-CoA reductase inhibitors, nonsteroidal anti-inflammatory drugs (NSAIDs), quinolones, and benzodiazepines.

Keep away from light, sealed and stored in a dry place.

1 mg

24 months

Beijing Hanmi Pharmaceutical Co., Ltd.

• Founded in:

  1996-03-27

• Address:

  No. 10, Tianzhu West Road, Area A, Tianzhu Airport Industrial Zone, Shunyi District, Beijing

• Tax NO.:

  91110113600048921K

• Registered Funds:

  630 million yuan

• Website:

  Log in to view

• Email:

  Log in to view